(Total Views: 905)
Posted On: 08/26/2020 5:44:04 PM
Post# of 154177
nice post by gladys1:
Received this email today. I guess we cannot construe this as negative or positive, but may be of interest.
This is in response to your email dated August 17, 2020, to the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).
Thank you for sharing your suggestion. Please be assured that NIH scientists are considering all potential therapies and are exploring the most promising treatment approaches for COVID-19. NIH and Operation Warp Speed (OWS) are aware of leronlimab and its potential for COVID-19 and are awaiting any promising results from the ongoing company-sponsored trial. OWS aims to deliver 300 million doses of a safe, effective vaccine for COVID-19 by January 2021, as part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (collectively known as countermeasures).
Thank you for contacting NIAID.
Sincerely,
Kara M. Harris, MPH
Section Chief for Controlled Correspondence and Public Inquiries
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Received this email today. I guess we cannot construe this as negative or positive, but may be of interest.
This is in response to your email dated August 17, 2020, to the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH).
Thank you for sharing your suggestion. Please be assured that NIH scientists are considering all potential therapies and are exploring the most promising treatment approaches for COVID-19. NIH and Operation Warp Speed (OWS) are aware of leronlimab and its potential for COVID-19 and are awaiting any promising results from the ongoing company-sponsored trial. OWS aims to deliver 300 million doses of a safe, effective vaccine for COVID-19 by January 2021, as part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (collectively known as countermeasures).
Thank you for contacting NIAID.
Sincerely,
Kara M. Harris, MPH
Section Chief for Controlled Correspondence and Public Inquiries
Legislative Affairs and Correspondence Management Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases
National Institutes of Health
(4)
(0)
